Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.65 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880413 | 0.88 | POLB (0.76) | MGLLSMPD1POLBMEN1KMT2A | |
| SCHEMBL11246226 | 0.88 | POLB (0.76) | MGLLSMPD1POLBMEN1KMT2A | |
| SCHEMBL11240645 | 0.88 | POLB (0.76) | MGLLSMPD1POLBMEN1KMT2A | |
| SCHEMBL931440 | 0.86 | POLB (0.73) | MGLLSMPD1POLBNPC1RAB9A | |
| SCHEMBL2800438 | 0.83 | SMPD1 (0.62) | MGLLSMPD1POLBL3MBTL1MEN1 | |
| SCHEMBL598032 | 0.83 | SMPD1 (0.62) | MGLLSMPD1POLBL3MBTL1MEN1 | |
| SCHEMBL10958244 | 0.83 | SMPD1 (0.62) | MGLLSMPD1POLBL3MBTL1MEN1 | |
| SCHEMBL6356934 | 0.82 | HDAC3 (0.74) | MGLLSMPD1POLBMEN1KMT2A | |
| SCHEMBL11761148 | 0.82 | POLB (0.84) | SMPD1POLBMEN1KMT2ANPC1 | |
| SCHEMBL1042188 | 0.81 | SMPD1 (0.60) | SMPD1POLBMEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | MGLL 1342/4885SMPD1 182/4885POLB 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.